oMeds
All answers
Answer · metabolic

Does semaglutide improve insulin resistance?

Short answer

Yes. Semaglutide improves insulin sensitivity through two reinforcing mechanisms: direct GLP-1 receptor effects on insulin and glucagon secretion, and indirect improvement from substantial weight loss. Fasting insulin, HOMA-IR, and A1c all measurably improve in most candidates.

Reviewed by Dr. Laura PurdyMay 29, 2026

Full answer

Yes. Semaglutide improves insulin sensitivity through two reinforcing mechanisms. Directly, GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite — all of which lower the glycemic and insulin load. Indirectly, the substantial weight loss that follows (particularly visceral fat loss) reduces the inflammatory and free-fatty-acid signals that drive insulin resistance in the first place. In the major trials, fasting glucose, fasting insulin, HOMA-IR, and hemoglobin A1c all improved meaningfully — often within the first 3 months and continuing to improve as weight loss compounded. Semaglutide is not a substitute for resistance training, sleep, and nutrition (which preserve muscle and durability of the response), and it is provider-reviewed for candidacy and side-effect management.

Educational. Not a substitute for individualized provider review.

References & sources
  • Semaglutide pathway — Primary source · oMeds
  • Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-05-29

Related pathways

All pathways →

Related answers

Does semaglutide cause muscle loss?
GLP-1 therapy drives weight loss that includes both fat and lean mass — typically ~25–40% of total weight lost is lean tissue when no countermeasures are applied. Lean-mass loss is largely preventable with adequate protein intake, resistance training, and provider-reviewed titration; it is a protocol issue, not an inevitability of the molecule.
Is tirzepatide better than semaglutide?
Head-to-head trials show tirzepatide drives larger average weight loss and greater A1C reduction than semaglutide. Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a GLP-1 mono-agonist. 'Better' depends on candidacy, tolerance, insurance access, cardiovascular history, and the targeted endpoint — it is a provider-reviewed match, not a universal winner.
What is insulin resistance?
Insulin resistance is a state where cells respond poorly to insulin, so the pancreas secretes more insulin to maintain normal blood glucose. It precedes type-2 diabetes by years and shows up first in fasting insulin, HOMA-IR, triglyceride/HDL ratio, and ApoB before A1C or fasting glucose drift. It is reversible.
Does tirzepatide lower A1c?
Yes. Tirzepatide produces some of the largest A1c reductions seen with any non-insulin therapy — frequently 1.5–2.5 percentage points in patients with type 2 diabetes — through combined GLP-1 and GIP receptor activation plus substantial weight loss.
Preserving muscle on GLP-1?
Muscle preservation on a GLP-1 is engineered, not incidental. The three levers are protein intake (typically ≥1.6 g/kg/day), resistance training (2–4 sessions/week), and avoiding excessive caloric deficit. Provider-reviewed GLP-1 pathways include this architecture rather than the molecule alone.
Primary source
Semaglutide pathway